Skip to main content
Premium Trial:

Request an Annual Quote

Qlucore, Nebion to Promote Each Other's Data Analysis Products

NEW YORK (GenomeWeb News) – Bioinformatics firms Qlucore and Nebion today announced a collaboration to promote each other's data analysis products.

Under the terms of the deal, they will promote Qlucore Omics Explorer and Nebion's Genevestigator. Financial and other terms were not disclosed.

Qlucore Omics Explorer is a software program for exploring and analyzing high dimensional datasets interactively and in real time. Genevestigator is a web platform that integrates expression data and curated sample annotations, enabling the "systematic screening of the database for genes that have unique expression properties and validation of target and biomarker genes by checking how they respond to thousands of experimental conditions," the partners said.

Genevestigator originated as an academic project of the Swiss Federal Institute of Technology. Zurich-based Nebion took over development of the product in 2008 and then commercialized it.

In a statement Qlucore CEO Carl-Johan Ivarsson said that "Nebion complements the Qlucore product offering perfectly by enabling a web-based systematic screening of genes across many thousand experiments, so it makes perfect sense to work together to provide a broader solution to our clients."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.